@article{34a824f7f9e642cd97d34b3b50a6516d,
title = "Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)",
abstract = "Follicular lymphoma is the most common form of lymphoma in Europe and the USA. In this prospective, single-arm, open-labelled, multicentre non-randomised phase II trial (FLUMIZ [FLUdarabine, MItoxantrone, Zevalin] trial) we aimed to assess the efficacy and safety of fludarabine and mitoxantrone plus radioimmunotherapy in untreated patients with follicular non-Hodgkin lymphoma (NHL).",
keywords = "Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Italy, Kaplan-Meier Estimate, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Male, Maximum Tolerated Dose, Middle Aged, Mitoxantrone, Neoplasm Staging, Probability, Radioimmunotherapy, Risk Assessment, Survival Analysis, Vidarabine, Yttrium Radioisotopes, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Italy, Kaplan-Meier Estimate, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Male, Maximum Tolerated Dose, Middle Aged, Mitoxantrone, Neoplasm Staging, Probability, Radioimmunotherapy, Risk Assessment, Survival Analysis, Vidarabine, Yttrium Radioisotopes",
author = "Voso, {Maria Teresa} and Pl Zinzani and M Tani and A Pulsoni and M Gobbi and A Perotti and {De Luca}, S and A Fabbri and A Zaccaria and P Fattori and L Guardigni and S Ronconi and Mg Cabras and L Rigacci and {De Renzo}, A and E Marchi and V Stefoni and M Fina and C Pellegrini and G Musuraca and E Derenzini and S Pileri and S Fanti and Pp Piccaluga and M. Baccarani",
year = "2008",
doi = "10.1016/S1470-2045(08)70039-1",
language = "English",
volume = "9",
pages = "352--358",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "The Lancet:6277 Sea Harbor:Orlando, FL 32887:(800)462-6198, EMAIL: uslancetcs@elsevier.com, INTERNET: http://www.thelancet.com, Fax: (407)363-1354",
}